FACP FACRA - Mesoblast CEO, Founder
| MESO Stock | USD 13.54 0.38 2.89% |
Insider
FACP FACRA is CEO, Founder of Mesoblast
| Age | 65 |
| Phone | 61 3 9639 6036 |
| Web | https://www.mesoblast.com |
Mesoblast Management Efficiency
The company has return on total asset (ROA) of (0.0541) % which means that it has lost $0.0541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1791) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Gary MD | Verrica Pharmaceuticals | 48 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Amro Albanna | Aditxt Inc | 55 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| MS MBA | Inozyme Pharma | 48 | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Terence Kohler | Verrica Pharmaceuticals | N/A | |
| CPA CPA | Lipocine | 54 | |
| Lei Sun | Connect Biopharma Holdings | 61 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| DDS MS | Aditxt Inc | 59 | |
| Iraj Ali | Achilles Therapeutics PLC | 50 | |
| CPA CPA | Aditxt Inc | 56 | |
| Janet CA | Aptose Biosciences | N/A | |
| Daniel Welch | Nuvation Bio | 63 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Anne McKay | Fennec Pharmaceuticals | 70 | |
| Michael Esq | Fortress Biotech Pref | 57 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 |
Mesoblast Leadership Team
Elected by the shareholders, the Mesoblast's board of directors comprises two types of representatives: Mesoblast inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mesoblast. The board's role is to monitor Mesoblast's management team and ensure that shareholders' interests are well served. Mesoblast's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mesoblast's outside directors are responsible for providing unbiased perspectives on the board's policies.
| LLB BCom, Joint Secretary | ||
| Justin BS, Head Manufacturing | ||
| Marcelo Santoro, Chief Officer | ||
| Roger BA, Head Disorders | ||
| Fiona See, Senior Research | ||
| MS MBA, Chief Officer | ||
| BSc LLB, Gen Exec | ||
| FACP FACRA, CEO, Founder | ||
| Eric MD, Chief Director | ||
| Andrew BCom, Interim Officer | ||
| Paul BPHARM, Joint Secretary | ||
| MBA MS, Head Partnering | ||
| Dr BSc, Scientific Officer |
Mesoblast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mesoblast a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 | ||||
| Operating Margin | (12.49) % | ||||
| Current Valuation | 1.79 B | ||||
| Shares Outstanding | 114.18 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 1.38 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 3.62 X |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.